The HGF/c-MET pathway has been shown to mediate vascular endothelial growth factor receptor (VEGFR) inhibitor resistance and vascular remodelling in non-small-cell lung cancer (NSCLC) 31. The gene discussed is MET; the disease is non-small cell lung carcinoma.